{"name":"Scientific Center for Anti-infectious Drugs, Kazakhstan","slug":"scientific-center-for-anti-infectious-drugs-kazakhstan","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Efesovir","genericName":"Efesovir","slug":"efesovir","indication":"Other","status":"phase_2"},{"name":"FS-1","genericName":"FS-1","slug":"fs-1","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Efesovir","genericName":"Efesovir","slug":"efesovir","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"FS-1","genericName":"FS-1","slug":"fs-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE5qU2dPUFFiVnJ4N0NFOXR3b0ZCTzkzbTdMT2VIX0JwZ3gxczRXb3dISU1KNmxhWFY2VGs1enhCMVE2M290UHJLX0VYSTBDNFVYcVdiOFNOc0hLc3dQdHFQZ3VaZw?oc=5","date":"2025-08-21","type":"pipeline","source":"QS GEN","summary":"Pharmaceutical Technology Synergy - QS GEN","headline":"Pharmaceutical Technology Synergy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5JbHhMZ2Qwd01yLVdQakh2M2NhWHFVSmlsNXo5SEhIekZQTTc1OWJfWlJNdm42LVNaY2EweUg0VUN5alFNQUI5OHlfSmtEWDVjcUphbmVhN1Rsb25tT2c?oc=5","date":"2025-08-13","type":"trial","source":"ACS Publications","summary":"Evaluation of the Therapeutic Efficacy of the Newly Formulated Drug “Novostron” as an Experimental Basis for Clinical Trials - ACS Publications","headline":"Evaluation of the Therapeutic Efficacy of the Newly Formulated Drug “Novostron” as an Experimental Basis for Clinical Tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWHAzWjFFMENjYlBES3lKbk5pUXpvZ09pM1FxWGpmQTg4LXBLWmpYMGZuVHpqckFPb2VGdzd4VDloTE12MmxMSzBnRFZRNEdYWXhhbGZYUjBBT05UNGRKX3hZSDI0VlhSTGU2NVFWQ1VyZjZnUjdHRXF6UnRrNExNNUg1MXNxd0d4SG5WWVNSYTVtSWZzVVBzNl9NLTNZWFgybEVrU2Z4RUQxZw?oc=5","date":"2022-08-26","type":"trial","source":"Pharmaceutical Technology","summary":"PAN-TB’s Phase II trials take a shot at shorter TB regimens - Pharmaceutical Technology","headline":"PAN-TB’s Phase II trials take a shot at shorter TB regimens","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}